---
document_datetime: 2025-09-11 14:41:20
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/taltz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: taltz-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 10.1527044
conversion_datetime: 2025-12-15 20:00:15.584217
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Taltz

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                              |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------|
| II/0053              | Extension of indication for TALTZ to include treatment alone or in combination with methotrexate, of active JPsA and ERA in patients 6 years of age and older and with a body weight of at least 25 kg, who have had an inadequate response to, or who are intolerant of, conventional therapy, based on week 16 results from study I1F-MC-RHCG. | 24/07/2025                          | 22/08/2025                                  | SmPC and PL                      | Please refer to Scientific Discussion: Taltz EMEA/H/C/003943/II/0053 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been updated. Furthermore, the PI is in line with the latest QRD template version 10.4. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                          |            |            |                        |                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------|
| II/0054             | Update section 4.8 of the SmPC to add eczematous eruptions (dyshidrotic eczema and exfoliative dermatitis) to the list of adverse drug reactions (ADRs) with frequency uncommon and rare, respectively, following a review of all associated data. The package leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 12/06/2025 | 22/08/2025 | SmPC and PL            | Not applicable SmPC new text For more information, please refer to the Summary of Product Characteristics. |
| X/0051              | Extension application to add a new strength of 40 mg for Taltz, Solution for injection Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                            | 30/01/2025 | 28/03/2025 | SmPC, Labelling and PL |                                                                                                            |
| PSUSA/10493 /202403 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 31/10/2024 | n/a        |                        | PRAC Recommendation - maintenance                                                                          |

<div style=\"page-break-after: always\"></div>

| IA/0050   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 28/05/2024   | n/a        |             |                                                                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------|
| II/0049/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                  | 20/04/2023   | n/a        |             |                                                                               |
| II/0048   | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol                                                                                                                                                                                                                                                                                       | 09/02/2023   | n/a        |             |                                                                               |
| II/0046   | Update of section 4.8 of the SmPC in order to add 'oesophageal candidiasis' to the list of adverse drug reactions (ADRs) with frequency rare based on a safety review of all associated data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update instructions for use to clarify information on product stability at room temperature. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 12/01/2023   | 05/01/2024 | SmPC and PL | For more information, please refer to the Summary of Product Characteristics. |

<div style=\"page-break-after: always\"></div>

| IG/1565   | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 06/12/2022   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0045/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.II.a.3.b.5 - Changes in the composition (excipients) of the finished product - Other excipients - Change that is supported by a bioequivalence study B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products | 16/12/2021   | 28/11/2022 | SmPC, Labelling and PL | As a result of this group of variations, sections 4.8 and 6.1 of the SmPC are being updated to reflect that the introduction of a citrate free formulation to improve tolerability. Section 4.8 of the SmPC is updated as follows: The results described above are obtained with the original formulation of Taltz. In a single-blinded, randomized cross- over study in 45 healthy subjects comparing the original formulation with the revised, citrate-free formulation, statistically significantly lower VAS pain scores were obtained with the citrate-free vs. the original formulation during injection (difference in LS Mean VAS score -21.69) and 10 min after injection (difference in LS Mean VAS score -4.47). Section 6.1 of the SmPC is updated as follows: Sucrose Polysorbate 80 Water for injections Sodium hydroxide may be used to adjust pH |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        | accordingly (concerning ingredients). For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10493 /202103 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                               | 28/10/2021 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| T/0044              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 29/07/2021 | 12/08/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0040             | Update of section 5.1 of the SmPC with long-term efficacy and safety data in axial spondyloarthritis from study RHBY - A multicenter, long-term extension study of 104 weeks, including a double-blind, placebo-controlled 40-week randomized withdrawal-retreatment period, to evaluate the maintenance of treatment effect of ixekizumab in patients with axial spondyloarthritis. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/06/2021 | 12/08/2021 | SmPC                   | Patients who completed one of the three Axial Spondyloarthritis pivotal studies COAST V/W/X (52 weeks) were offered participation in a long term extension and randomised withdrawal study (COAST Y, with 350 and 423 patients enrolled on Taltz Q4W and Q2W, respectively). Among those who achieved remission 157/773 (20.3%) (Ankylosing Spondylitis Disease Activity Score [ASDAS] <1.3 at least once, and no ASDAS score ≥2.1, at weeks 16 and 20), 155 patients exposed to Taltz up to 76 weeks were randomised at week 24 of the COAST Y study (Placebo, N=53; Taltz Q4W, N=48; and Taltz Q2W, N=54); of these, 148 (95.5%) completed the week 64 visit (Placebo, N=50; Taltz Q4W, N=47; Taltz Q2W, N=51). The primary endpoint was the proportion of patients in the randomised withdrawal population who did not experience a flare during weeks 24 64 (combined Taltz Q2W and Taltz Q4W groups versus placebo). A significantly larger proportion of patients (NRI) in the combined Taltz groups (83.3% (85/102), p<0.001) and Taltz Q4W (83.3% (40/48), p=0.003) had no flare during weeks 24 64 compared with those who withdrew from Taltz to placebo (54.7% (29/53)). Taltz (in both combined Taltz groups and |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |      | Taltz Q4W group) significantly delayed the time to flare (Log Rank Test p<0.001 and p<0.01, respectively) compared to Placebo. In patients who received Taltz Q4W continuously (N=157), the ASAS40, ASDAS<2.1 and BASDAI50 responses were maintained to Week 116. In conclusion, data from the randomized placebo-controlled withdrawal-retreatment study shows that, in patients who achieved sustained remission, continuous treatment with ixekizumab reduces the likelihood of experiencing a flare.   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0041   | B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                                                                                                                                                        | 11/03/2021 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IB/0042   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                              | 05/03/2021 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0038/G | This was an application for a group of variations. Clinical studies in adult plaque psoriasis: Type II- C.I.4 -Update of section 5.1 of the SmPC regarding long term data in the treatment of psoriasis: RHAZ, RHBA, RHBC (3 studies of the 'UNCOVER' series) were the pivotal registration studies, with response data up to 60 weeks already included in the SmPC. The current update relates to the extension data available, covering a total of 5 years. | 14/01/2021 | 12/08/2021 | SmPC | The long-term efficacy data from the studies submitted in plaque psoriasis and psoriatic arthritis supports a long term sustained efficacy in this adult population treated with Taltz. The risk profile from these additional studies is also consistent with the known safety profile for Taltz (described in the currently approved SmPC), and there were no new clinically important safety findings with this long-term data submission.                                                              |

<div style=\"page-break-after: always\"></div>

|        | information from study RHCR (known as 'IXORA-R') which is a 24-week head-to-head comparison of Taltz vs guselkumab. Clinical studies in adult psoriatic arthritis: Type II- C.I.4 -Update of section 5.1 of the SmPC regarding long term data in the treatment of psoriatic arthritis: RHAP and RHBE (also known as SPIRIT-P1 and P2) were pivotal registration studies, with response data at 24 weeks and up to 52 weeks (SPIRIT-P1) already included in the SmPC. The current update relates to extension data available covering a total of 3 years. Section 5.1 of the SmPC has also been updated with longer-term data from study RHCF ('SPIRIT-H2H' Taltz vs adalimumab). Response data of up to 24 weeks are already in the SmPC and the addition of 52 week data are being made. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   |            |            |                        |                                                                                                                                                                                                                                                                     |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0039 | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/10/2020 | 17/12/2020 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Taltz in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10493 /202003   | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/10/2020   | n/a        |                                  | PRAC Recommendation - maintenance                               |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-----------------------------------------------------------------|
| II/0034               | B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 02/07/2020   | n/a        |                                  |                                                                 |
| II/0031               | Extension of Indication to include the treatment of moderate to severe plaque psoriasis in children from the age of 6 years and with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. The PI was also brought in line with the latest QRD template version 10.1. The RMP version 7.2 has also been agreed. The variation leads to amendments to the Summary of Product Characteristics, Annex II, and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 28/05/2020   | 26/06/2020 | SmPC, Annex II, Labelling and PL | Please refer to Scientific Discussion 'Taltz-H-C-003943-II- 31' |
| IB/0035               | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 24/06/2020   | 17/12/2020 | SmPC and PL                      |                                                                 |
| IAIN/0037/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/06/2020   | n/a        |                                  |                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                |            |            |             |                                                                 |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------|
| II/0030 | Extension of indication to include treatment of adult patients with active axial spondyloarthritis; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC and relevant section of the PL are updated. The PI was also brought in line with the latest QRD template version 10.1. Furthermore, the applicant took the opportunity to update the local representative of Estonia in the PL. In addition, the RMP was updated to version 6.3. The variation leads to amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 30/04/2020 | 02/06/2020 | SmPC and PL | Please refer to Scientific Discussion 'Taltz-H-C-3943-II- 0030' |
| IB/0033 | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/04/2020 | n/a        |             |                                                                 |

<div style=\"page-break-after: always\"></div>

|                     | of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0032              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/03/2020 | 02/06/2020 | PL   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10493 /201903 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 03/10/2019 | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0029/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                 | 08/08/2019 | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0026/G           | This was an application for a group of variations. Type II- C.I.4 -Update of section 5.1 of the SmPC based on results of study RHCF - a 52-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naïve. Type II- C.I.4 -Update of section 4.5 of the SmPC based on results of study RHBU - a study evaluating of the effect of ixekizumab on the pharmacokinetics of cytochrome P450 substrates in patients with | 18/07/2019 | 02/06/2020 | SmPC | The Product information has been updated with results from a drug-drug interaction study in patients with moderate-to-severe psoriasis, which determined that 12 weeks of administration of ixekizumab with drugs metabolized by CYP3A4 (i.e., midazolam), CYP2C9 (i.e., warfarin), CYP2C19 (i.e., omeprazole), CYP1A2 (i.e., caffeine) or CYP2D6 (i.e., dextromethorphan) does not have a clinically significant impact on the pharmacokinetics of these drugs. In addition, results from a study investigating the efficacy and safety of Taltz in a multicenter, randomized, open- label, rater-blinded, parallel-group study (SPIRIT-H2H) compared to adalimumab (ADA) in 566 patients with PsA |

<div style=\"page-break-after: always\"></div>

|                     | moderate-to-severe plaque psoriasis. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data     |            |     | who were naïve to biologic disease-modifying anti- rheumatic drugs (bDMARD) were also reflected in the product information. Taltz was superior to ADA on the primary study objective: simultaneous achievement of ACR 50 and PASI 100 response at Week 24 (Taltz 36.0% vs ADA 27.9%; p=0.036; 95% confidence interval [0.5%, 15.8%]). Taltz also showed non-inferiority (pre-specified margin of -12%) to ADA on ACR 50 ((ITT analysis: 3.9% difference vs. ADA; 95% confidence interval [-4.3%; 12.1% ; PPS analysis Taltz: 52.3%, ADA: 53.1%, difference: -0.8% [CI: -10.3%; 8.7%]) and superiority on PASI 100 at Week 24 (60.1% with Taltz vs 46.6% with ADA, p=0.001), which were the major secondary endpoints in the study.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027             | B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method                                                        | 23/05/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10493 /201809 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                     | 11/04/2019 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0025/G           | This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.b - Change to importer, batch release | 14/02/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     | Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method   |            |            |             |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10493 /201803 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                             | 04/10/2018 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0021             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                          | 29/08/2018 | n/a        |             |                                   |
| IB/0022             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                 | 20/08/2018 | n/a        |             |                                   |
| N/0023              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                     | 30/07/2018 | 06/02/2019 | PL          |                                   |
| II/0018             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                    | 25/05/2018 | 06/02/2019 | SmPC and PL |                                   |
| II/0014             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                               | 26/04/2018 | n/a        |             |                                   |
| II/0016             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                    | 19/04/2018 | 06/02/2019 | SmPC and PL |                                   |
| PSUSA/10493 /201709 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                             | 12/04/2018 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0017           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 15/02/2018   | n/a        |             |                                                                                                                                            |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0898             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                    | 12/02/2018   | 06/02/2019 | Annex II    |                                                                                                                                            |
| II/0009             | Extension of Indication to include Ixekizumab alone or in combination with methotrexate, the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, and 5.2 of the SmPC are updated to reflect the new safety and efficacy information. The Package Leaflet and RMP have been updated accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 14/12/2017   | 18/01/2018 | SmPC and PL | Please refer to the published Assessment Report Taltz H- 3943-II-09-AR.                                                                    |
| PSUSA/10493 /201703 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/10/2017   | 08/12/2017 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10493/201703. |
| IB/0012/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/10/2017   | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0011             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 31/08/2017 | n/a |                                   |
| IB/0008             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 26/04/2017 | n/a |                                   |
| PSUSA/10493 /201609 | Periodic Safety Update EU Single assessment - ixekizumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 06/04/2017 | n/a | PRAC Recommendation - maintenance |
| IA/0007             | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 07/02/2017 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0006   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                         | 14/12/2016   | n/a        |                  |           |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------|-----------|
| IAIN/0004 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                   | 15/11/2016   | n/a        |                  |           |
| N/0002    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                     | 14/10/2016   | 07/09/2017 | Labelling and PL |           |
| IB/0003   | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                                                                                                                                                                                                                                                                                                             | 12/10/2016   | 07/09/2017 | SmPC and PL      |           |
|           | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 02/06/2016   | n/a        |                  | IA/0001/G |